VDR-silent vitamin D derivative as inhibitors of SREBP and pharmaceutical use thereof

A compound of formula (I):

• or a stereoisomer, mixture of stereoisomers, and/or a pharmaceutically acceptable salt thereof,
• wherein
• the double bond from a to b is in the E-configuration or Z-configuration;
• R1 is hydrogen;
• where Ra and Rb together with the carbon to which they are attached form an unsubstituted C5-C7-cycloalkyl group;
• —CH2—S-(heteroaryl);
• —CH2-(1,3-dioxo-isoindolin-2-yl);
• (ortho-carboranyl);
• —CH2—NH-(phenyl);
• or
• R2a, R2b, R3, R3a, R3b, R4, R4a, and R4b are independently selected from hydrogen and halo;
• one of X and Y is CR5 and the other is CH;
• or one of X and Y is CR5 and the other is N;
• R5 is hydrogen;
• C1-C6-alkyl;
• hydroxy-C1-C6-alkyl;
• aryl optionally substituted with 1, 2, or 3 R5a groups;
• or 5- or 6-membered heteroaryl optionally substituted with 1, 2, or 3 R5a groups;
• each R5a is independently hydrogen, alkyl, haloalkyl, or halo;
• and
• wherein each phenyl and heteroaryl group are independently optionally substituted with 1, 2, 3, 4, or 5 groups independently selected from the group consisting of halogen, halo-C1-4 alkyl, —S-(halo-C1-4 alkyl), C1-4 alkoxy, halo-C1-4 alkoxy, nitro, cyano, and C1-4 alkoxycarbonyl;
• and
• provided that the compound is not
• or a stereoisomer, mixture of stereoisomers, and/or a pharmaceutically acceptable salt thereof.